首页> 外文期刊>Herz >Mid-term results after stentless mitral valve replacement. Comparison to conventional mitral valve replacement and mitral valve repair
【24h】

Mid-term results after stentless mitral valve replacement. Comparison to conventional mitral valve replacement and mitral valve repair

机译:无支架二尖瓣置换术后的中期结果。与常规二尖瓣置换和二尖瓣修复的比较

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the clinical results after stentless (SMV) in comparison to mitral valve repair (MV-rep) and conventional mitral valve replacement (MVR) at 5 years. PATIENTS AND METHODS: From 08/1997 onward, 155 patients with degenerative mitral valve (MV) disease received an SMV (n=53, 68+/-8 years, 37 female), MV-rep (n=51, 69+/-9 years, 32 female), or MVR (n=51, 66+/-9 years, 32 female). The underlying MV disease was stenosis in 13 (SMV)/1 (MV-rep)/4 (MVR), incompetence in 13 (SMV)/50 (MV-rep)/30 (MVR), and combined lesion in 27 (SMV)/0 (MV-rep)/12 (MVR) patients, respectively. Preoperative New York Heart Association (NYHA) functional class was 3.1+/-0.6 (SMV)/2.9+/-0.5 (MV-rep)/2.9+/-0.6 (MVR), Euroscore 5.2+/-2.3 (SMV), 5.0+/-1.9 (Mv-rep), 4.8+/-2.6 (MVR), left ventricular ejection fraction 60.5+/-10% (SMV)/57.3+/-13% (MV-rep)/58.7+/-13% (MVR), and cardiac index 2.1+/-0.8/2+/-0.7/2+/-0.8 l/min/m2 (not significant). Follow-up includes 64+/-18 months (21-89 months). RESULTS: Surgery was performed via conventional sternotomy (32 SMV/20 MVR-rep/34 MVR) or right anterolateral minithoracotomy (21/31/17). Cross-clamp duration was 81+/-33 (SMV)/58+/-24 (MV-rep)/54+/-23 min (MVR; p<0.05). Mean pressure gradients amounted to 4.8+/-1.9/3.6+/-1.7/4.3+/-1.4 mmHg, and valve opening areas to 2.5+/-0.6/3+/-0.9/2.6+/-0.9 cm2, respectively. In-hospital mortality was 1 (SMV)/2 (MV-rep)/5 (MVR) patients (p<0.05). During follow-up, repeat surgical interventions were required in 6 (SMV)/2 (MV-rep)/3 (MVR) patients. 5-year survival was 80.5+/-4.4% (SMV)/82.6+/-5.6% (MV-rep)/80.2+/-5.5% (MVR; not significant); this was comparable to an age-matched normal population. CONCLUSION: At 5 years, the SMV compares favorably with conventional standards when taking the patients' risk profile into account. The SMV with its reliable functional and hemodynamic outcome may be the mitral prosthesis of choice in future.
机译:目的:与二尖瓣修复(MV-rep)和常规二尖瓣置换(MVR)在5年时相比,评估无支架(SMV)后的临床结果。患者与方法:从08/1997开始,有155例退行性二尖瓣(MV)病患者接受了SMV(n = 53、68 +/- 8岁,37位女性),MV-rep(n = 51、69 + / -9岁,女32岁)或MVR(n = 51,66 +/- 9岁,女32岁)。潜在的MV疾病是狭窄(13(SMV)/ 1)(MV-rep)/ 4(MVR),无能(13(SMV)/ 50(MV-rep)/ 30(MVR))和合并病变(27(SMV) )/ 0(MV-rep)/ 12(MVR)患者。术前纽约心脏协会(NYHA)的功能等级为3.1 +/- 0.6(SMV)/2.9 +/- 0.5(MV-rep)/2.9 +/- 0.6(MVR),Euroscore 5.2 +/- 2.3(SMV), 5.0 +/- 1.9(Mv-rep),4.8 +/- 2.6(MVR),左心室射血分数60.5 +/- 10%(SMV)/57.3 +/- 13%(MV-rep)/58.7 +/- 13%(MVR),心脏指数为2.1 +/- 0.8 / 2 +/- 0.7 / 2 +/- 0.8 l / min / m2(不显着)。随访时间为64 +/- 18个月(21-89个月)。结果:手术通过常规胸骨切开术(32 SMV / 20 MVR-rep / 34 MVR)或右前外侧小切口开胸术(21/31/17)进行。交叉钳夹持续时间为81 +/- 33(SMV)/ 58 +/- 24(MV-rep)/ 54 +/- 23 min(MVR; p <0.05)。平均压力梯度总计为4.8 +/- 1.9 / 3.6 +/- 1.7 / 4.3 +/- 1.4 mmHg,阀门打开面积分别为2.5 +/- 0.6 / 3 +/- 0.9 / 2.6 +/- 0.9 cm2。住院死亡率为1(SMV)/ 2(MV-rep)/ 5(MVR)患者(p <0.05)。在随访期间,需要对6例(SMV)/ 2(MV-rep)/ 3例(MVR)患者进行重复手术干预。 5年生存率为80.5 +/- 4.4%(SMV)/82.6 +/- 5.6%(MV-rep)/80.2 +/- 5.5%(MVR;不显着);这与年龄匹配的正常人群相当。结论:5年时,考虑到患者的风险状况,SMV优于常规标准。具有可靠功能和血流动力学结果的SMV可能是将来选择的二尖瓣假体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号